BMAL1 and Burkitt lymphoma: Bu Y. et al. identified that miR-211 directly targets to Bmal1 and Clock in Burkitt’s lymphoma, thereby suppressing both circadian oscillation and ongoing protein synthesis to facilitate tumor progression (Bu et al., 2018).